Evidences for mineralocorticoid excess in essential hypertension;Exceso de mineralocorticoides en hipertensos esenciales: Enfoque clínico-diagnóstico

Revista Medica de Chile

Volumn 128, Issue 9, 2000, Pages 955-961

  Cortés P , Paola ^a   Fardella B , Carlos ^a   Oestreicher C , Eveline ^a   Gac E , Homero ^a   Mosso G , Lorena ^a   Soto M , Julia ^a   Foradori C , Arnaldo ^a   Claverie R , Ximena ^a   Ahuad N , Jessica ^a   Montero L , Joaquín ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Aldosterone; Hyperaldosteronism; Hypertension

Indexed keywords

ALDOSTERONE; POTASSIUM; RENIN;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; REFERENCE VALUE;

ADULT; AGED; ALDOSTERONE; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; POTASSIUM; REFERENCE VALUES; RENIN;

EID: 0034281126     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. DANNENBERG AL, GARRISON RJ, KANNEL WB. Incidence of hypertension in the Framingham study. Am J Public Health 1988; 78: 676-9.
2. BERRÍOS X, JADUE L, ZENTENO J, ROSS MI, RODRÍGUEZ H. Enfermedades crónicas del adulto. Estudio de algunos factores de riesgo en población general urbana de la Región Metropolitana, 1986-1987. Rev Méd Chil 1990; 118: 1042-3.
3. The Sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Meet 1997; 157: 2413-46.
4. CONN JW, COHEN EL, ROVNER DR, NESBIT RM. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension. JAMA 1965; 193: 200-6.
5. GANGULY A. Primary aldosteronism. Review article. N Engl J Med 1998; 339: 1828-34.
6. BLUMENFELD JD, SEALEY JE, SCHLUSSEL Y, VAUGHAN ED JR, SOS TA, ATLAS SA, MULLER FB, ET AL. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-85.
7. KOMIYA I, YAMADA T, AIZAWA T, TAKASU N, NIWA A, MARUYAMA Y, OGAWA A. Inappropriate elevation of the aldosterone/plasma renin activity ratio in Hypertensive patients whit increases of 11-deoxycorticosterone and 18-hydroxy-11-deoxycorticosterone: a subtype of essential hypertension?. Cardiology 1991; 78: 99-110.
8. GORDON RD, ZLESAK MD, TUNNY J, STOWASSER M, KLEMM SA. Evidence that primary aldosteronism may not be uncommon: 12% Incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-8.
9. MOSSO L, FARDELLA C, MONTERO L, ROJAS P, SANCHEZ O, ROJAS V, ROJAS A, HUETE A, SOTO J, FORADORI A. Alta prevalencia de hiperaldosteronismo primario no diagnosticado en hipertensos catalogados como esenciales. Rev Méd Chile 1999; 127: 800-6.
10. FARDELLA C, MOSSO L, GÓMEZ-SÁNCHEZ C, CORTÉS P, SOTO J, GÓMEZ L, PINTO M, HUETE A, OESTREICHER E, FORADORI A, MONTERO J. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-7.
11. FARDELLA C, MONTERO M, MOSSO L. Hipertensión arterial y mineralocorticoides: Utilidad de las mediciones de renina y aldosterona. Rev Méd Chil 1999; 127: 604-10.
12. MCKENNA TJ, SEQUEIRA SJ, HEFFERNAN A, CHAMBERS J, CUNNINGHAM S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73: 952-7.
13. GORDON R. Mineralocorticoid hypertension. Lancet 1994; 344: 240-3.
14. LINS PE, ADAMSON U. Plasma aldosterone-plasma renin activity ratio: a simple test for primary aldosteronism. Acta Endocrinol (Copenh) 1986; 113: 56.
15. MENARD J, CORVOL P, ALLEGRINI J, BREMINER J. Methode de mesure de l'activite rénine plasmatique de l'homme par le dosage radioimmunologique de l'angiotensine I. In Techniques Radioimmunologiques. INSERM Publication 1972; 459-69.
16. MONTERO J, SOTO J, FARDELLA C, FORADORI A, VALDÉS G. Medición de la actividad de renina plasmática a niveles bajos. optimización del método. Rev Méd Chil 1998; 126: 151-4.
17. BROWN MA, CRAMP HA, ZAMMIT VC, WHITWORTH JA. Primary hyperaldosteronism: a missed diagnosis in "essential hypertensives"?. Aust NZ J Med 1996; 26: 533-8.
18. BRAVO EI. Primary aldosteronism: issues in diagnosis and management. Endocrinol Metab Clin North Am 1994; 23: 271-83.
19. LIFTON R, DLUHY RG, POWERS M, RICH GM, COOK S, ULICK S, LALOVEL JM. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 335: 262-5.
20. PASCOE L, CURNOW K, SLUTSKER L, CONNELL JM, SPEISEK PW, NEW MI, WHITE PC. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossover between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992; 89: 8327-31.
21. FARDELLA CE, RODRIGUEZ H, HUM DW, MELLON SH, MILLER WL. Artificial mutations in P450c11AS (aldosterone synthase) can increase enzymatic activity: a model for low-renin hypertension? J Clin Endocrinol Metab 1995; 80: 1040-3.
22. FARDELLA CE, RODRIGUEZ H, MONTERO J, ZHANG G, VIGNOLO P, ROJAS A, VILLARROEL L, ET AL. Genetic variation in P450c11AS in Chilean patients with low renin hypertension. J Clin Endocrinol Metab 1996; 81: 4347-51.
23. FARDELLA C, ZAMORANO P, MOSSO L, GÓMEZ L, PINTO M, SOTO J, OESTREICHER E, CORTÉS P, CLAVERIE X, MONTERO J. A-6G variant of angiotensinogen gene and aldosterone levels in hypertensives. Hypertension 1999; 34 [part 2]: 779-81.
24. MONTERO J, FARDELLA CE, MOSSO L. Hipertensión arterial tratable con glucocorticoides: comunicación de un caso. Rev Méd Chil 1997; 15: 1361-5.
25. DLUHY R, LIFTON. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995; 60: 48-51.
26. FAUDELLA CE, MILLER WL. Molecular biology of mineralocorticoid metabolism. Annu Rev Nutr 1996; 16: 443-70.
27. FARDELLA CE, ZHANG LH, MAHACHOKLERTWATTANA P, LIN D, MILLER WL. Deletion of amino acids Asp487-Ser488-Phe489 in human cytochrome P450c17 causes severe 17-hydroxylase deficiency. J Clin Endocrinol Metab 1993; 77: 489-93.
28. FARDELLA CE, HUM DW, HOMOKI J, MILLER WL. Point mutation Arg440 to His in cytochrome P450c17 causes severe 17-hydroxylase deficiency. J Clin Endocrinol Metab 1994; 79: 160-4.
29. NEW MI, LEVINE LS, BIGLIERI EG, PAREIRA J, ULICK S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977; 924-33.
30. WILSON RC, KROZOWSKI ZS, LI K, OBEYESEKERE VR, RAZZAGHY-AZAR M, HARBISON JQ. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995; 80: 2263-6.
31. MUNE T, ROGERSON FM, NIKKILA H, AGARWAL AK, WHITE PC. Human hypertension caused by mutations in the kydney isozyme 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995; 10: 395-9.
32. LIDDLE GW, BLEDSOE T, COPPAGE WS. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 1963; 76: 199-213.
33. BOTERO-VÉLEZ M, CURTIS JJ, WARNOCK DG. Brief report: Liddle's syndrome revisited. N Engl J Med 1994; 330: 178-81.